Navigation Links
Novel drug combination offers therapeutic promise for hard-to-treat cancers
Date:9/12/2011

Boston, MA - Researchers at Brigham and Women's Hospital (BWH) have identified a new combination of targeted therapies that, together, may treat two aggressive tumor types that until now have not had effective treatments. These findings are published in Cancer Cell on September 13, 2011.

While numerous anti-cancer drugs are being developed, many tumors do not respond to currently available single therapies. As such, there is a major push to identify new drug combinations that can work together to treat these resistant cancers . The drug combination identified by BWH researchers was shown to successfully treat two models of aggressive cancers: a nervous system tumor associated with neurofibromatosis type 1, and KRAS-mutant lung cancer, a form of lung cancer that accounts for about 25 percent of all lung cancers. "Without a targeted treatment that works, these two cancers are currently being treated with chemotherapy with variable success," said Dr. Karen Cichowski, Associate Professor in Genetics at BWH and lead author of the paper. "By identifying a more effective targeted treatment, the outcome and survival rate for these cancers may see a drastic improvement, and patients may avoid the typical side-effects of chemotherapy."

Researchers took the approach of combining two targeted agents, one the mTOR inhibitor rapamycin, which suppressed tumor growth, along with the HSP90 inhibitor IPI-504 from Infinity Pharmaceuticals, which triggers a specific kind of stress in cancer cells. Together, but not alone, these drugs promoted dramatic tumor regression in these two distinct cancers in mice. "It's like hitting the tumor cell from two different angles," explains Dr. Cichowski. "Using one drug to put on the brakes and another to apply stress to an already stressed cancer cell, which ultimately triggers its self-destruction".

These studies have inspired the testing of a drug combination that is now in a Phase I clinical trial, specifically in KRAS-mutant lung cancer. "The identification of this promising therapeutic combination sets the stage for developing other combinations and may also prove effective in other cancers through further research," said Dr. Cichowski.


'/>"/>

Contact: Holly Brown-Ayers
hbrown-ayers@partners.org
617-534-1603
Brigham and Women's Hospital
Source:Eurekalert

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... DORTMUND, Germany , February 28, 2017 ... ... Amsterdam from 14 to 16 March, ... to destination, and show how seamless travel is a real benefit ... Materna has added biometrics to their passenger touch point solutions to ...
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber ... announced it has led a $3.5 million investment in  ... platform. Strategic Cyber Ventures is DC based and is ... Hank Thomas . Ron Gula , also ... Ventures, also participated in this series A round of ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... ... proud to announce it has become the premiere team-building cooking event company in San Diego. ... such as Illumina, HP and Qualcomm, and is ranked #1 in its category on Trip ... its new team building format, a way for teams to not only interact with one ...
(Date:3/23/2017)... Calif., March 23, 2017  BioPharmX Corporation (NYSE ... for the dermatology market, today reported financial results ... 2017, and will provide an update on the ... year. "We are pleased to report ... for BioPharmX," said President Anja Krammer. "We achieved ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), ... technology to address significant unmet medical needs in ... full year ended December 31, 2016. ... company as we broadened our pipeline and pursued ... disease company with an initial focus on endocrinology," ...
Breaking Biology Technology: